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Background: Psychoactive substance use and misuse of prescription medication is 
prevalent among the general population. We aimed to ascertain the prevalence of 
psychoactive substance use (asides alcohol), misuse of prescription medications and level 
of risk of patients visiting three primary care clinics in Benin-City, Edo State. 
Methods:  In this cross-sectional study, 649 participants were recruited from three 
health facilities using systematic random sampling technique. The World Health 
Organization’s Alcohol, Smoking and Substance Involvement Screening Test (WHO 
ASSIST) was administered to participants. Bivariate analysis was used to determine 
association between socio-demographic variables and psychoactive substance use.  P-
value < 0.05 was employed as level of statistical significance. 
Results: Opioid pain medication was the most commonly ever used substance by 
participants   with a lifetime prevalence of 55.6% (n=361) and a prevalence for current 
use of 40.2% (n=261).  Males compared to females were more likely to be daily or weekly 
users of tobacco (p<0.001) and marijuana in the last three months (p=0.003). The 
widowed compared to the married or singles were more likely to indulge in daily or weekly 
use of sedatives (p=0.02) and opioid pain medication (p=0.001) in the past three months. 
One hundred and ninety-six (30.2%) of the participants demonstrated moderate risk 
while 4 (0.6%) demonstrated high risk to opioid pain medication use. Being male was 
significantly associated with the risk of adverse effects of tobacco (p=<0.001), marijuana 
(p=0.002) and stimulant use (p=0.002).  
Conclusion: Routine screening for psychoactive substance use and misuse of 
prescription medication is recommended in primary care facilities. 
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Federal Neuropsychiatric Hospital,  
P.M.B.1108, Benin-City,  






Psychoactive substance use is not a new 
phenomenon and it is of major public health 
concern globally.1, 2 Its negative 
consequences impact on individuals, their 
families and the society at large. 3 According 
to the United Nations Office on Drug Crime, 
about a quarter of a billion (250 million) of 
the population had used illicit drugs in 
2015. Cannabis was reported as the most 
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commonly used illicit substance with a past 
year prevalence of about 183 million people. 
4 In a national survey conducted in 2015 
among non-institutionalized civilians in the 
United States (US), it was reported that 11.5 
million people had a history of opioid misuse 
while 1.9 million reported an opioid 
prescription use disorder. 5 In a descriptive 
national survey of substance use conducted 
in 2009 among 10,609 participants aged 15-
64 years in the six geopolitical zones of 
Nigeria, the authors reported that cannabis 
was the most commonly used illicit drug 
with a lifetime use of 6.6%, 12-month use of 
2.6% and 30-day use of 1.8%. 6   
Substance misuse is the use of a substance 
for a purpose not consistent with legal or 
medical guidelines while hazardous use 
refers to a pattern of substance use that 
increases the risk of harmful consequences 
for the user, that is, patterns of use that are 
of public health significance in the absence 
of any current disorder in the individual. 7 
Harmful use is defined as a pattern of 
psychoactive substance use that is causing 
damage to health; which may either be 
physical or mental.8 Dependence syndrome 
is a cluster of physiological, behavioural, 
and cognitive phenomena in which the use 
of a substance or a class of substances takes 
on a much higher priority for a given 
individual than other behaviours that once 
had greater value.7 “Problematic use” is a 
term applied to those in whom substance 
use has caused substance- related disorder 
or disability; including those who abuse and 
those who are dependent on the substance.9  
The World Drug Report of 2017 stated that 
about 0.6% of the global adult population 
were involved in problematic use of 
psychoactive substances, thus suffering 
from psychoactive substance use disorders. 
4 Psychoactive substance use disorder is a 
major contributor to the global burden of 
diseases. 10 For instance, a 2017 report 
attributed 17 million disability adjusted life 
years (DALYs) to drug use disorders 4 while 
a risk assessment study conducted in 
Canada using exposure data and risk 
relations from large studies and meta 
analyses reported that cannabis use was 
associated with 287 deaths and 66346 
DALYs.11   
Substance use and substance use disorders 
predispose the users to a wide variety of 
health and social problems, consequently 
affecting the society at large. 12,13 For 
example, injection drug use is associated 
with a risk of contracting HIV and Hepatitis 
C due to sharing of needles and other 
injecting instruments among users. 4 
Methamphetamine abuse is associated with 
cardiac problems, depression and dental 
problems. 14   Non-medical use of cannabis 
is associated with impaired respiratory 
function, increased risk for accidents and 
mental disorders like anxiety, panic 
symptoms including frank psychosis. 15 The 
use of these substances is also associated 
with deviant and criminal behaviours. 16 
Psychoactive substance use (PSU) is also 
associated with poor health outcomes in 
many medical conditions, its co-occurrence 
with these conditions usually complicating 
their management. 17-19 
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A number of studies on psychoactive 
substance use have been carried out in 
primary care   facilities, however, most of 
these studies focused on either alcohol or 
licit substance use such as prescription 
medications 20-22 with very few focusing on 
other psychoactive substances and their 
level of risk to use of these substances. 
Considering that the primary care centres 
are usually patients’ first contact to medical 
care and they present in such centres with 
other medical problems which may be 
related to substance use, 23-25 such centres 
thus provide an effective avenue for the 
assessment and provision of appropriate 
interventions for psychoactive substance 
use before it becomes an established 
disorder. 26, 27 Moreover, identification of 
those with non-problematic substance use 
disorder and implementing appropriate 
intervention towards this group will have 
positive impact on the society, considering 
the economic, psychological and social 
consequences of an established substance 
use disorder on the affected individual and 
the society.  
This study aimed to assess the prevalence of 
psychoactive substance use (other than 
alcohol), and misuse of prescription 
medications, their pattern of use and the 
level of risk associated with the use of these 
substances among attendees of three 
primary care clinics in Benin City, Nigeria. 
Furthermore, the socio-demographic 
correlates of pattern of use and level of risk 
to these substances were also assessed. 
 
METHODOLOGY 
This is a cross-sectional study on the 
prevalence of psychoactive substance use 
and misuse of prescription medication, the 
pattern of use and level of risk to these 
substances among people attending three 
primary care clinics in Benin City, Nigeria. 
Data for the study was collected from 
August 2016 to January 2017. This study 
was conducted at three health facilities 
providing primary care services in Benin-
City. These were: the General Practice Clinic 
of the University of Benin Teaching Hospital 
(UBTH [GPCU]), the Medical Clinic of the 
Federal Neuropsychiatric Hospital (FNPH 
[MCF]), and the General Out-Patient 
Department of the General Hospital, Benin 
City (GH[GOPDG]).  
UBTH is a tertiary centre which receives 
referrals from other neighbouring health 
facilities.  The GPC unit delivers primary 
care services to staff members and students 
of the university, including the community 
around the university environment. It has a 
daily turnout of about 220 patients and no 
referrals are required before patients are 
attended to. FNPH is a 230-bed facility 
which provides in-patient and out-patient 
care, as well as emergency services to 
mentally ill persons primarily across the 
South-South region (a geographical 
catchment area of six states) of Nigeria. The 
MC provides primary care services to 
medically-ill persons from the surrounding 
communities.  An average of 10-15 patients 
are seen in a day. The GH is a secondary 
health care facility which provides both in-
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patient and out-patient services but the 
GOPD section which provides primary 
health care services was used for this study. 
The facility has an average patient load of 
320-350 per day and 220-230 new cases per 
clinic day. 
The study population comprised all 
attendees of the hospitals aged between 14 
years and 59 years, whose condition was not 
too severe to impair their ability to respond 
to questions. Data for those aged 60 years 
and above have been discussed in another 
paper. (In press). Patients aged between 14-
59 years were recruited for this study.  
Ideally, participants should be aged 18 
years and above (due to issue of consent) 
but on account of the high prevalence of 
psychoactive substance use in teenagers, 
we included this age group in the study. 
Those with severe physical or mental illness 
and those who did not understand English 
Language nor Pidgin English were excluded 
from the study. Also excluded were those 
who did not consent to participate in the 
study. 
The following formula was used to calculate 
the minimum sample size for the study. n = 
z2pq/ d2 28; where z is the normal standard 
deviate 1.96 at 95% confidence interval and 
p is the prevalence of psychoactive 
substance use of 33.7% as reported by 
Igwe.29 Thus, the minimum sample size was 
345. 
Systematic random sampling technique was 
employed at each centre to select 
participants. The sampling interval for the 
various clinics differed as the patient load in 
each centre was unequal. Thus, we 
calculated the sampling interval based on 
the average amount of patients seen at the 
different clinics. In cases where the nth 
patient was not eligible, the next patient was 
recruited for the study. The first participant 
was however selected through a simple 
random method from the first nth patients 
registered for the day. 
Ethical approval was obtained from the 
Research and Ethical Committee of the 
Federal Neuropsychiatric Hospital, Benin 
City and the Ethics and Research 
Committee University of Benin Teaching 
Hospital, Benin City. Permission was sought 
from the Director of Hospital Services before 
patients were recruited from the State 
General Hospital. Informed consent (both 
verbal and written) was obtained from 
participants before being recruited. 
Informed consent to participate was 
obtained from parents or guardian of those 
younger than 18 years while assent of these 
under-aged were sought. Confidentiality 
was maintained by obtaining data 
anonymously using serial numbers instead 
of names, these were kept in a safe place 
where it was inaccessible to those not 
involved in the study. Participants were 
informed of their right to withdraw from the 
study at any point and that this would not 
interfere adversely with their treatment. All 
participants were given appropriate 
intervention during the interview.  
A clinician-designed structured 
questionnaire to assess the socio-
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demographics of participants was used for 
the study. The variables included age, sex, 
marital status, level of education, 
occupational status, religion and previous 
treatment for substance use. Misuse of 
prescription medication was determined as 
medications taken for reasons other than 
prescription, or taking them more frequently 
or at higher doses than prescribed.30 
The Alcohol, Smoking, Substance 
Involvement Screening Test (ASSIST) 30 
This is an eight-item interviewer-
administered questionnaire that screens for 
all levels of problems or risky substance 
use. It screens for the following substances; 
tobacco products, alcohol, cannabis, 
cocaine, amphetamine type stimulants, 
sedative and sleeping pills, hallucinogen, 
inhalants, opioids and ‘other drugs’. It 
obtains information about lifetime use 
(lifetime prevalence) of substances and use 
of substance with associated problems in 
the last three months (current prevalence). 
A risk score was provided for each 
substance and scores were grouped into 
low, moderate or high risk.  For each 
substance (asides alcohol), a score of 0-3 
denotes low risk, 4-26 moderate risk, 27+ 
high risk. Moderate risk depicts harmful or 
hazardous use while high risk depicts a high 
risk for dependence. The risk scores 
determine the level of intervention 
(treatment as usual [drug education] for 
those with low or no risk, brief intervention 
for those with moderate risk or referral to a 
specialist centre for those with high risk). 
This instrument has undergone testing in 
three phases to ensure feasibility, validity 
and reliability. 31, 32 It has been validated 
and used extensively in Nigeria including in 
primary care centres. 20, 31, 33, 34  
A pilot study was conducted prior to the 
main study to determine feasibility of the 
study, easiness of questionnaire 
administration and administration time of 
research instruments. The pilot study 
showed that the questionnaire was easy to 
administer and acceptable to over 95% of 
the participants. An average administration 
time of about 10 minutes was observed for 
each interview. The participants involved in 
the pilot study were excluded from the main 
study. Interviews were conducted by two 
research assistants trained extensively on 
the administration of the ASSIST by (A.F.T). 
Inter-rater reliability was good with a value 
of 0.7 for Cohen’s kappa. 
Eligible participants were selected using the 
systematic random sampling technique at 
the general outpatient hall, while awaiting 
their turn to see the doctor. They were then 
taken to a private room within the 
outpatient clinic for questionnaire 
administration. All participants were given 
the appropriate treatment after discussing 
their scores with them at point of data 
collection. The attending physician was also 
informed of those who needed referral for 
more intensive treatment as recommended 
by the algorithm in the WHO ASSIST 
questionnaire. 
Analysis was done using the Statistical 
Package for Social Sciences (SPSS) version 
20.0 Descriptive statistics (mean, standard 
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deviation) was carried out. The ASSIST 
score was used (according to the manual) to 
categorize the level of risk into low, 
moderate or high risk.  Some variables were 
grouped together or categorised to improve 
statistical power. All categorized data were 
analysed using chi square test of 
association. Fisher’s exact test/ Bonferroni 
correction was implemented where 
appropriate. P-value < 0.05 was employed 
as level of statistical significance. 
RESULTS 
A total of 649 participants were recruited 
from the three primary care clinics.  
Females comprised majority of the 
participants 371 (57.2%).  The mean age of 
participants was 37.5 years (±11.55). Those 
aged 31-40 years comprised the 
predominant age group 188 (29%). Majority 
of the participants possessed secondary 
level of education 263 (40.5%). The socio-
demographic variables of participants are 
outlined in Table 1. 
Lifetime prevalence of psychoactive 
substance use 
 Table 2 shows the prevalence of lifetime use 
and current use of psychoactive substances 
by participants. Opioid pain medication was 
the most common ever used psychoactive 
substance at the three primary care clinics 
with a lifetime prevalence of 55.6% (n=361). 
This was closely followed by stimulant use 
with a lifetime prevalence of 34.1 % (n= 
221).   
 
 
Table 1: Sociodemographic Characteristics of 
Participants 
Variable  Frequency 
(n=649) 
Percent  
Sex    
Female  371                                                     57.2
Male  277 42.7 
 
Age group (years) 
  
14-20 32 4.9 
21-30 180 27.7 
31-40 188 29.0 
41-50 136 21.0 




Single 200 30.8 
Married 431 66.4 




Managerial/Technical 8 1.2 
Professional 33 5.1 
Skilled 99 15.3 
Semi-skilled 82 12.6 
Unskilled 305 47.0 




Primary 119 18.3 
Secondary 263 40.5 




Christian 617 95.1 
Islam 13 2.0 
*n≠649 for some variables due to missing values. 
NOC: not otherwise classified (unemployed, 
housewife, students) 
 
The least used substance was hallucinogen 
with a lifetime prevalence of 0.2% (n=1). 
Current use psychoactive substances 
In all three centres, the common 
psychoactive substances used by the 
participants in the past three months. 
Opioid pain medication was the most used 
substance currently in all three centres with 
a current prevalence of 40.2% (n=261).  This 
was closely followed by mild stimulant use 
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Table 2: Lifetime and Current Prevalence of 
Psychoactive Substance Use 
Variables Lifetime Use Current Use 
   
             Yes         Yes   
















Sedative  110 16.9 44 6.8 
Marijuana 33 5.1 13 2.0 
Inhalant  14 2.2 4 0.6 
Cocaine 6 0.9 3 0.5 
Hallucinogen  1 0.2 0 0.0 
     
 
The prevalence of sedative use in the last 
three months by participants was also high 
with a current prevalence of 6.8% (n=44).  
Hallucinogen was the least used substance 
in all centres with a current prevalence of 
0.0% (n=0). (Table 2). 
Pattern of psychoactive substance use in 
the last three months 
Table 3 describes the pattern of use for 
psychoactive substances in the past three 
months by the participants. Eighty-four 
(12.9%) of the participants used opioid pain 
medications daily or weekly in the past three 
months while 23 participants (3.5%) had 
used tobacco either daily or four times 
weekly in the past three months.  Again, 
2.5% of the participants reported a daily or 
weekly use of mild stimulants and sedatives 
in the past three months.  
Table 3: Pattern of Use of Psychoactive    
Substances in Past Three Months 














Amphetamine  633 (97.5) 16 (2.5) 







Weekly: four times or more in a week 
 
Socio-demographics and pattern of 
psychoactive substance use in the last 
three months 
Tobacco: Males were significantly more 
likely to indulge in tobacco use daily or four 
times weekly in the past three months 
compared to the females (7.2% vs 0.8%; 
p<0.001). 
Marijuana: The males compared to the 
females used marijuana daily or weekly in 
the last three months (3.2% vs 0.3%; 
p=0.003). Participants from other religious 
affiliations compared to the Muslims and 
Christians were more likely to use 
marijuana daily or four times weekly in the 
past three months and this was statistically 
significant (p=0.01).  
Sedatives: The widowed compared to those 
who were married or single were more likely 
to use sedatives daily or four times weekly 
in the last three months (p=0.02). 
Heroine: Those who were widowed 
compared to their married and single 
counterparts were more likely to have used 
opioid pain medications daily or four times 
weekly in the last three months (p=0.001). 
Similarly, those with either no formal or 
primary level of education compared to their 
counterparts with secondary or tertiary level 
of education were more likely to use opioid 
pain medication daily or four times weekly 
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Table 4: Level of Participants Risk to Adverse Effects of Psychoactive Substance Use
Substance Low Moderate High 















      0 (0.0)     
      0 (0.0) 
      0 (0.0) 
      1 (0.2) 
      9 (1.4) 
    29 (4.5) 








Amphetamine  607 (93.5)     41 (6.3) 1 (0.2) 
Heroine/Opioid 449 (69.2) 196 (30.2) 4 (0.6) 
Others  649 (100.0)       0 (0.0) 0 (0.0) 
 
Level of risk of psychoactive substance 
use 
Table 4 shows the level of risk exhibited by 
participants to the adverse effects of use of 
these psychoactive substances using the 
algorithm of the WHO ASSIST 
questionnaire. Among the participants in 
these facilities, 196 (30.2%) demonstrated 
moderate risk to opioid use while 4 (0.6%) 
demonstrated high risk to its use. Forty-one 
(6.3%) of these participants demonstrated 
moderate risk to stimulant use while only 
one participant (0.2%) demonstrated high 
risk to its use.  Concerning the use of 
tobacco and marijuana, 3 (0.5%) 
demonstrated high risk to tobacco use, 
while 5 (0.8%) demonstrated high risk to 
marijuana use.  However, all participants 
(100%) demonstrated low risk to the use of 
inhalants, hallucinogens and injury risk.  
Socio-demographics and level of risk 
Tables 5a to 5c describes the socio-
demographic correlates of the level of risk of 
adverse effects of psychoactive substance 
use. 
Tobacco: Being male was significantly 
associated with a risk of the adverse effects 
of tobacco use (p<0.001). The Christians 
were more likely to be at risk of the adverse 
effects of tobacco use compared to the 
Muslims and those affiliated to other 
religion (p=0.02). 
Marijuana: Males compared to females were 
more likely to be at risk of the adverse effects 
of marijuana use (p=0.002), while those 
affiliated with other religion compared to the 
Muslims or Christians were more at risk of 
the adverse effects of marijuana use 
(p=0.002). 
Stimulant: The males were significantly 
more likely to exhibit high risk to the 
adverse effect of mild stimulant use 
compared to the females (p=0.002). Those 
aged within 41-50 years were more at risk of 
experiencing the adverse effects of 
stimulants use compared to other age 
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Table 5a: Participants’ Socio-demographic Characteristics and Level of Risk to adverse effects of Psychoactive Substances  





















TOBACCO     MARIJUANA     
Sex     Sex     
Female   366 (98.7) 4 (1.1) 1 (0.3) <0.001* Female  369 (99.5) 2 (0.5)  0 (0.0)              0.002* 
Male  244 (88.1) 31 (11.2) 2 (0.7)  Male  265 (95.7) 7 (2.5)  5 (1.8) 
 
Age (years) 
     
Age (years) 
    
14-20 31 (96.9) 1 (3.1) 0 (0.0) 0.25 14-20 32 (100.0) 0 (0.0)  0 (0.0)              0.54 
21-30 




















185 (98.4)  
134 (98.5) 











     
Marital Status 
    











193 (96.5)   
10 (100.0)      
4 (2.0) 
0 (0.0) 




     
Education  
    
None/Primary  110 (92.4) 8 (6.7) 1 (0.8) 0.12 None/Primary  117 (98.3) 2 (1.7)  0 (0.0)             0.52+ 
Secondary  244 (92.8) 18 (6.8) 1 (0.4)  Secondary   259 (98.5) 3 (1.1)  1 (0.4) 
Tertiary  241 (96.8) 8 (3.2) 0 (0.0)  Tertiary  242 (97.2) 3 (1.2)  4 (1.6) 
 
Religion  
     
Religion  
    
Christian 587 (95.1) 28 (4.5) 2 (0.3) 0.02bfs Christian 607 (98.4) 7 (1.1)  3 (0.5)             0.002* 
Islam 

















     
Occupation  
    
Managerial/Tech 8(100.0) 0 (0.0) 0 (0.0) 0.94 Managerial/Tech 8 (100.0) 0 (0.0)  0 (0.0)              0.34 
Professional  32 (97.0) 1 (3.0) 0 (0.0)  Professional 33 (100.0)          0 (0.0)  0 (0.0) 
Skilled 92 (92.9) 6 (6.1) 1 (1.0)  Skilled 95 (96.0) 1 (1.0)  3 (3.0) 
Partly skilled 79 (96.3) 3 (3.7) 0 (0.0)  Partly skilled 81 (98.8) 1 (1.2)  0 (0.0) 
Unskilled 285 (93.4) 19 (6.2) 1 (0.3)  Unskilled 297 (97.4) 7 (2.3)  1 (0.3) 
NOC 110 (94.8) 5 (4.3) 1 (0.9)  NOC 115 (99.1) 0 (0.0)  1 (0.9) 








JOURNAL OF COMMUNITY MEDICINE AND PRIMARY HEALTH CARE VOL. 32, NO 1, MARCH 2020 
 
Table 5b: Participants’ Socio-demographic Characteristics and Level of Risk to adverse effects of Psychoactive 
Substances  
Variable/Substance Level of Risk p-
value 
Variable/Substance Level of Risk p-value 
 Low Mod High   Low Mod High  
 n (%) n (%) n (%)   n (%) n (%) n (%)  
COCAINE     AMPHETAMINE     
Sex     Sex     
Female 370 (99.7) 1 (0.3) 0 (0.0) 1.0+ Female 357 (96.2) 14 (3.8) 0 (0.0) 0.002* 
Male 277 (100.0) 0 (0.0) 0 (0.0)  Male 249 (89.9) 27 (9.7) 1 (0.4)  
 
Age (years) 
     
Age (years) 
    
14-20 32 (100.0) 0 (0.0) 0 (0.0) 0.2+ 14-20 30 (93.8) 2 (6.2) 0 (0.0) 0.003bfs* 
21-30 180 (100.0) 0 (0.0) 0 (0.0)  21-30 176 (97.8) 4 (2.2) 0 (0.0)  
31-40 188 (100.0) 0 (0.0) 0 (0.0)  31-40 180 (95.7) 8 (4.3) 0 (0.0)  
41-50 136 (100.0) 0 (0.0) 0 (0.0)  41-50 121 (89.0) 14 (10.3) 1 (0.7)  
51-59 111 (99.1) 1 (0.9) 0 (0.0)  51-59 99 (88.4) 13 (11.6) 0 (0.0)  
 
Marital status 
     
Marital Status 
    
Married 430 (99.8) 1 (0.2) 0 (0.0) 1.0+ Married 399 (92.6) 31 (7.2) 1 (0.2) 0.09 
Single 200 (100.0) 0 (0.0) 0 (0.0)  Single 192 (96.0) 8 (4.0) 0 (0.0)  
Widow 10 (100.0) 0 (0.0) 0 (0.0)  Widow 8 (80.0) 2 (20.0) 0 (0.0)  
 
Occupation 
     
Occupation 
    
Managerial/Technical 8 (100.0) 0 (0.0) 0 (0.0) 1.0+ Managerial/Tech 6 (75.0) 2 (25.0) 0 (0.0)  
Professional 33 (100.0) 0 (0.0) 0 (0.0)  Professional 33 (100) 0 (0.0) 0 (0.0)  
Skilled 99 (100.0) 0 (0.0) 0 (0.0)  Skilled 89 (89.9) 9 (9.1) 1 (1.0)  
Partly skilled 82 (100.0) 0 (0.0) 0 (0.0)  Partly skilled 78 (95.1) 4 (4.9) 0 (0.0)  
Unskilled 304 (99.7) 1 (0.3) 0 (0.0)  Unskilled 285 (93.4) 20 (6.6) 0 (0.0)  
NOC 116 (100.0) 0 (0.0) 0 (0.0)  NOC 110 (94.8) 6 (5.2) 0 (0.0)  
 
Education 
     
Education 
    
No Formal/Primary 119 (100.0) 0 (0.0) 0 (0.0 )  No Formal/Primary 107 (89.9) 12 (10.1) 0 (0.0) 0.10 
Secondary 263 (100.0) 0 (0.0) 0 (0.0)  Secondary 245 (93.2) 17 (6.5) 1 (0.4)  
Tertiary 248 (99.6) 1 (0.4) 0 (0.0)  Tertiary 239 (96.0) 10 (4.0) 0 (0.0)  
 
Religion 
     
Religion 
    
Christian 616 (99.8) 1 (0.2) 0 (0.0)  Christian 579 (93.8) 37 (6.0) 1 (0.2) 0.27+ 
Islam 13 (100.0) 0 (0.0) 0 (0.0)  Islam 11 (84.6) 2 (15.4) 0 (0.0)  
Others 11 (100.0) 0 (0.0) 0 (0.0)  Others 10 (90.9) 1 (9.1) 0 (0.0)  




Some substances were found to be 
commonly used among the attendees of the 
three primary care clinics, while others were 
rarely used. Generally, the rates of 
substances reported in this study are higher 
than the reports from a national survey of 
substance use previously conducted among 
the general population in Nigeria. 6 The 
national survey found a lifetime/current 
use in the following decreasing order of 
prevalence: tobacco (12.2%/5.3%), 
tranquillizers (11.3%/2.9%), and opiates 
(7.2%/2.2%). Cocaine and hallucinogens 
remained the least likely used substances 
according to the report. 6 Comparatively, the 
pattern of substance use in terms of the 
order of use is dissimilar for the commonly 
used ones, while minor differences exist for 
the less prevalent ones. 
The prevalence of substances such as 
tobacco, which is not a prescription drug, 
did not differ markedly from what was 
reported in the national survey, whereas, 
higher prevalence rate of prescription drugs 
such as tranquilizers and opiates was found 
in our study when compared to the national 
survey. This is understandable because our 
study participants consist of clinic patients, 
with medical condition(s) which can 
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Table 5c: Participants’ Socio-demographic Characteristics and Level of Risk to adverse effects of Psychoactive 
Substances  
Variable/Substance Level of Risk p-
value 
Variable/Substance Level of Risk p-
value 
 Low Mod High   Low Mod High  
 n (%) n (%) n (%)   n (%) n (%) n (%)  
SEDATIVES     HEROINE     
Sex      Sex      
Female 351 (94.6) 19 (5.1) 1 (0.3) 0.55 Female 256 (69.0) 113 (30.5) 2 (0.5) 0.95 
Male 267 (96.4) 10 (3.6) 0 (0.0)  Male 193 (69.7) 82 (29.6) 2 (0.7)  
 
Age (Years) 
     
Age (Years) 
    
14-20 32 (100.0) 0 (0.0) 0 (0.0) 0.29+ 14-20 24 (75.0) 8 (25.0) 0 (0.0) 0.67 
21-30 175 (97.2) 5 (2.8) 0 (0.0)  21-30 127 (70.6) 53 (29.4) 0 (0.0)  
31-40 179 (95.2) 9 (4.8) 0 (0.0)  31-40 133 (70.7) 54 (28.7) 1 (0.5)  
41-50 129 (94.9) 7 (5.1) 0 (0.0)  41-50 93 (68.4) 42 (30.9) 1 (0.7)  
51-59 103 (92.0) 8 (7.1) 1 (0.9)  51-59 71 (63.4) 39 (34.8) 2 (1.8)  
 
Marital  Status 
     
Marital Status 
    
Married 412 (95.6) 18 (4.2) 1 (0.2) 0.14+ Married 291 (67.5) 137 (31.8) 3 (0.7) 0.30 
Single 191 (95.5) 9 (4.5) 0 (0.0)  Single 146 (73.0) 53 (26.5) 1 (0.5)  
Widow 8 (80.0) 2 (20.0) 0 (0.0)  Widow 5 (50.0) 5 (50.0) 0 (0.0)  
 
Occupation 
     
Occupation 
    
Managerial/Tech 7 (87.5) 1 (12.5) 0 (0.0)  Managerial/Tech 6 (75.0) 2 (25.0) 0 (0.0) 0.17 
Professional 31 (93.9) 2 (6.1) 0 (0.0) 0.45+ Professional 25 (75.8) 8 (24.2) 0 (0.0)  
Skilled 96 (97.0) 3 (3.0) 0 (0.0)  Skilled 72 (72.7) 25 (25.3) 2 (2.0)  
Partly skilled 77 (93.9) 4 (4.9) 1 (1.2)  Partly skilled 65 (79.3) 17 (20.7) 0 (0.0)  
Unskilled 290 (95.1) 15 (4.9) 0 (0.0)  Unskilled 196 (64.3) 107 (35.1) 2 (0.7)  
NOC 112 (96.6) 4 (3.4) 0 (0.0)  NOC 79 (68.1) 37 (31.9) 0 (0.0)  
 
Education 
     
Education 
    
No Formal/Primary 111 (93.3) 8 (6.7) 0 (0.0) 0.13 No Formal/Primary 73 (61.3) 46 (38.7) 0 (0.0) 0.04bfns 
Secondary 256 (97.3) 7 (2.7) 0 (0.0)  Secondary 179 (68.1) 80 (30.4) 4 (1.5)  
Tertiary 236 (94.8) 13 (5.2) 0 (0.0)  Tertiary 181 (72.7) 68 (27.3) 0 (0.0)  
 
Religion 
     
Religion 
    
Christian 590 (95.6) 26 (4.2) 1 (0.2)  Christian 425 (68.9) 188 (30.5) 4(0.6) 0.95+ 
Islam 13 (100.0) 0 (0.0) 0 (0.0)  Islam 10 (76.9) 3 (23.1) 0 (0.0)  
Others 10 (90.9) 1 (9.1) 0 (0.0)  Others 8 (72.7) 3 (27.3) 0 (0.0)  
Bfs: bonferroni significant;; Bfns: bonferroni non-significant. 
+FET, *p<0.05 
 
contribute to substance use. For instance, 
patients with chronic pain are frequently 
seen in primary health care settings 35 and 
opioid-analgesics, which are effective pain 
relievers, are prescribed to treat such 
conditions. 36    Regrettably, this substance 
may not be prescribed with caution and an 
over-extended use may lead to dependence; 
or patients may be reluctant to stop use, 
hence, they proceed to self-medication. 36   
Tramadol, an example of an opioid, which is 
widely abused in this manner is 
unfortunately easy to purchase without 
prescription over the counter from 
pharmacy shops or ‘patent drug stores’ in 
the country of study. This same explanation 
applies to the high use of tranquillizers 
reported in this study: benzodiazepines, 
which are the common tranquillizers taken, 
are frequently used to improve sleep among 
persons suffering from insomnia who are 
likely to visit PHC. 37 Unfortunately, the 
abuse of some of these prescription drugs 
can worsen the medical condition, 
complicate management of the patient and 
at overdose lead to death. The high 
prevalence of some substances such as mild 
stimulant and tobacco could be because 
they are licit, thus they are cheap to 
procure. Sometimes they are administered 
for therapeutic purposes; for example, kola 
nut is often chewed to keep alert or as an 
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antitussive. 38   On the other hand, the illicit 
substances are low in prevalence because 
they are often not within the reach of people 
due to legal restriction, more so they are 
expensive to obtain. However, among these 
illicit substances, prevalence of marijuana 
use is relatively high, a report similar to the 
findings in other studies. 6, 39 This is so 
because it is cultivated in the region of 
study, thus it is readily available, accessible 
and affordable to use. The public health 
implication of this is that, the disease 
burden attributable to marijuana will be 
high because marijuana use can lead to 
compromised respiratory function, 
cardiovascular disease, negative effects on 
adolescent psychosocial development and 
mental health, and dependence syndrome. 
40 
Conversely, the prevalence rates of most 
substances in this study are lower than 
those reported in other studies carried out 
in primary health centres outside the 
country. 41, 42 For instance, in the survey 
carried out by McNeely and colleagues in an 
adult primary health centre, in New York, 
they found a lifetime/current use of 
tobacco, marijuana, opioids and stimulants 
to be: 59.4%/32.0%, 50.5%/17.8%, 
30.7%/10.0% and 13.9%/5.0%%, 
respectively. 41 The prevalence of opioids 
and stimulants in our study were higher 
than what McNeely and colleagues reported, 
it should be noted that there are differences 
in the composition of what was surveyed as 
opioids and stimulants. For example, the 
main stimulants available in this study 
comprised the mild ones such as caffeine 
which is very common, and consumed 
frequently as kola nut and sometimes as 
coffee; while the harder stimulants such as 
amphetamine and others were what 
McNeely and colleagues investigated in their 
study. Also, the opioids available in this 
study consisted predominantly of tramadol 
with very few use of heroine and other 
opioids, while the other harder forms of 
opioids such as heroine and morphine were 
what they studied. 41   Lower prevalence of 
substances such as marijuana in our study 
compared to others could be as a result of 
socio-legal reasons. Unlike in the USA, the 
use, sale and possession of marijuana are 
regarded as criminal offences in Nigeria. 
Therefore, the use is discouraged and the 
disclosure of use is also hidden. This may 
account for the lower prevalence in this 
study. 
In terms of daily users in the last three 
months, the high prevalence rates of opioid 
analgesic and tobacco use may be a 
reflection of the addictive nature of these 
substances. 43, 44 Drugs such as these used 
on a regular or daily basis will often cause 
interference in personal and occupational 
functioning because of increased amount of 
time spent to obtain or take the substance 
or to recover from its effects. The effect on 
such substances on the brain and 
behaviour may also lead to break down in 
interpersonal and social relations. 
Concerning the relationship of gender and 
frequency of use in the last three months, 
our results showed what has been 
consistently reported in previous studies: 
the male gender is known to be associated 
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with higher marijuana and tobacco 
use/abuse. 45-48 A combination of biological, 
sociocultural and environmental factors 
may be responsible for the male 
preponderance, 49, 50 moreover males are 
more likely to be involved in risky 
behaviours than females. 51 
Regarding the association between the 
widowed and regular use of opioids and 
sedatives, our postulate is that this category 
of persons who have lost their spouses are 
probably older, lonely and depressed thus 
more likely to experience pain and sleep 
problems that predisposed them to higher 
risk of using those substances regularly.  52 
For the relationship between the less/none 
formally educated persons and regular 
opioid use, our explanation is that persons 
with little or no education are less likely 
than the more literate ones to know the 
implication of regular drug use. A further 
explanation for this co-association could be 
that both share similar predisposing factors 
such as poverty, crime, unemployment and 
even genetics.53 
The association between traditional religion 
and marijuana use may suggest a poor drug 
regulation among adherents of such faith 
which contrast with most mainstream 
religions which discourage the use of 
psychoactive substances. 54 Previous 
studies have shown a relationship between 
drug use and those without religious 
involvement. 45, 54 It is worrisome that some 
of these drugs are taken at a level that is 
risky. Earlier surveys have shown a wide 
variation in the range of moderate to high 
risk use of these substances (16.1-72.0%), 
opioid (1.0-26.8%), marijuana (4.2-60.1%) 
and tranquilizers (1.5-29.8%). 41, 42, 55 Many 
of the substances surveyed in our study fell 
below the range reported in the cited 
studies. The reason for this discrepancy in 
result may be due to differences in sample 
population; for instance, the study by 
Dawson-Rose et al comprise HIV positive 
patients while that of Stringfellow et al 
comprise homeless patients whom are all 
more likely to be at a higher risk of 
substance use. 42, 55 
It is important to note that socio-
demographics such as the male gender and 
traditional religion were significantly and 
independently associated with a high level 
risky use of one psychoactive substance or 
the other and the reasons for this have been 
earlier discussed. Furthermore, an 
association between the age group and risky 
stimulant use was observed in this study. 
Finally, the pattern noted was an increasing 
order of prevalence of risky use with 
increasing age. Older persons take caffeine 
in the form of kola nut as an antitussive and 
for its centrally stimulating effects to 
improve cognition, while the younger ones 
especially students take it in form of coffee 
to keep alert and enable them withstand 
fatigue. 56 
Limitations and strength 
Some limitations are to be considered when 
interpreting our findings. Firstly, there is 
the possibility of lapses with recall for 
substances used in the past.  Secondly, 
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there is the tendency to respond in a socially 
desirable manner because it was a self-
report. Thirdly, the study is a cross-
sectional one and analysis carried out was 
bivariate, therefore, relationship found 
between substance use (risky use) and other 
variables cannot be said to be predictive of 
one another. Lastly, ASSIST which is used 
primarily as a screening tool was applied to 
identify substance use disorder. Even 
though it has been found to be valid among 
drug users in determining drug use 
disorders, 57, 58 a diagnostic instrument 
might be more useful. However, being a 
multi-centre study qualifies it as a strength 
of the study, even though the sample may 
not be representative of all the regions in the 
country.  
Conclusion 
The study has shown that opioid pain 
medication was the most commonly ever 
used substance by patients attending the 
primary care clinics, followed by stimulants, 
tobacco, and tranquillizers. While there 
were isolated association of some socio-
demographic variables with substance use 
prevalence and risky use, the male gender 
was more consistent than other variables in 
this relationship.  The study highlights the 
need for routine screening of patients for 
psychoactive substance use including 
misuse of prescription medications. Again, 
special attention should be given to the male 
gender because of the greater use of 
psychoactive substances among them. 
Acknowledgement: Oni M and Iyayi I.O for 
their assistance with data collection. 
Source of funding: This research received 
no grant from funding agencies in the 
public, commercial, or not-for-profit sectors. 
Conflict of interest: None declared by 
authors  
Authors’ contributions: ALFT was involved 
in study conceptualization, study design, 
data collection and analysis, manuscript 
write up. OOA was involved in study design, 
data collection and manuscript write up, 
OSO was involved in study 
conceptualization, design and data 
collection. EM was involved in data 
collection and manuscript write up. 
REFERENCES 
1.  Westermeyer J. Historical and social context 
of psychoactive substance use disorders. 
Clinical textbook of addictive disorders. 
2005: 16-34. 
2.  Zawilska JB. An expanding world of novel 
psychoactive substances: opioids. Frontiers 
in psychiatry. 2017; 8: 110. 
3.  World Health Organization. The involvement 
of nurses and midwives in screening and brief 
interventions for hazardous and harmful use 
of alcohol and other psychoactive 
substances. Geneva: World Health 
Organization; 2010. 
4.  Merz F. United Nations Office on Drugs and 
Crime: World Drug Report 2017. 2017. 
SIRIUS-Zeitschrift für Strategische Analysen. 
2018; 2(1): 85-86. 
5.  Han B, Compton W, Blanco C, Crane E, Lee 
J, Jones C. Prescription opioid use, misuse, 
and use disorders in US adults. Annals of 
Internal Medicine. 2017; 167(5): 293-301. 
84 
 
JOURNAL OF COMMUNITY MEDICINE AND PRIMARY HEALTH CARE VOL. 32, NO 1, MARCH 2020 
6.  Adamson T, Ogunlesi A, Morakinyo O, 
Akinhanmi A, Onifade P, Erinoshp I. 
Descriptive national survey of substance use 
in Nigeria. Journal of  Addiction Research & 
Therapy. 2015; 6(03): 234. 
7.  World Health Organization. Management of 
substance abuse. 2005. 
8.  World Health Organization. International 
statistical classification of diseases and 
related health problems: 10th revision (ICD-
10). http://wwwwhoint/classificatio 
ns/apps/icd/icd. 1992. 
9.  Harrison P, Fazel M. Shorter Oxford Textbook 
of Psychiatry: Oxford university press; 2017. 
10.  Degenhardt L, Hall W. Extent of illicit drug 
use and dependence, and their contribution 
to the global burden of disease. The Lancet. 
2012; 379(9810): 55-70. 
11.  Imtiaz S, Shield KD, Roerecke M, Cheng J, 
Popova S, Kurdyak P, et al. The burden of 
disease attributable to cannabis use in 
Canada in 2012. Addiction. 2016; 111(4): 
653-662. 
12.  Rehm J, Shield KD. Alcohol and mortality: 
global alcohol-attributable deaths from 
cancer, liver cirrhosis, and injury in 2010. 
Alcohol Research: Current Reviews. 2014; 
35(2): 174. 
13.  Rudd RA, Paulozzi LJ, Bauer MJ, Burleson 
RW, Carlson RE, Dao D, et al. Increases in 
heroin overdose deaths - 28 states, 2010 to 
2012. MMWR Morbidity and mortality weekly 
report. 2014; 63(39): 849. 
14. Hellem TL, Lundberg KJ, Renshaw PF. A 
review of treatment options for co-occurring 
methamphetamine use disorders and 
depression. Journal of addictions nursing. 
2015; 26(1): 14. 
15.  Hall W, Degenhardt L. The adverse health 
effects of chronic cannabis use. Drug testing 
and analysis. 2014; 6(1-2): 39-45. 
16.  Håkansson A, Berglund M. Risk factors for 
criminal recidivism–a prospective follow-up 
study in prisoners with substance abuse. 
BMC Psychiatry. 2012; 12(1): 111. 
17.  Zammit S, Moore TH, Lingford-Hughes A, 
Barnes TR, Jones PB, Burke M, et al. Effects 
of cannabis use on outcomes of psychotic 
disorders: systematic review. The British 
Journal of Psychiatry. 2008; 193(5): 357-363. 
18.  Mertens JR, Flisher AJ, Ward CL, Bresick GF, 
Sterling SA, Weisner CM. Medical conditions 
of hazardous drinkers and drug users in 
primary care clinics in Cape Town, South 
Africa. Journal of Drug Issues. 2009; 39(4): 
989-1014. 
19.  Jouanjus E, Lapeyre‐Mestre M, Micallef J, 
French Association of the Regional Abuse and 
Dependence Monitoring Centres (CEIP-A) 
Working Group on Cannabis Complications* 
Cannabis use: signal of increasing risk of 
serious cardiovascular disorders. Journal of 
the American Heart Association. 2014; 3(2): 
e000638.  
20. Fela-Thomas A, Onifade P, Lasebikan V. 
Screening for alcohol use and associated level 
of harm in a Primary Health Care Facility in 
Nigeria. Nigerian Journal of Psychiatry. 2016; 
14(1): 36-45. 
21. Kaner E, Bland M, Cassidy P, Coulton S, Dale 
V, Deluca P, et al. Effectiveness of screening 
and brief alcohol intervention in primary care 
(SIPS trial): pragmatic cluster randomised 
controlled trial. BMJ. 2013; 346: e8501. 
22.  Boscarino JA, Rukstalis M, Hoffman SN, Han 
JJ, Erlich PM, Gerhard GS, et al. Risk factors 
for drug dependence among out‐patients on 
opioid therapy in a large US health‐care 
system. Addiction. 2010; 105(10): 1776-
1782. 
23. Morasco BJ, Dobscha SK. Prescription 
medication misuse and substance use 
disorder in VA primary care patients with 
chronic pain. General Hospital Psychiatry. 
2008; 30(2): 93-99. 
24.  Pedersen KM, Andersen JS, Søndergaard J. 
General practice and primary health care in 
Denmark. The Journal of the American Board 
of Family Medicine. 2012; 25(Suppl 1): S34-
S38. 
25.  Muldoon LK, Hogg WE, Levitt M. Primary care 
and primary health care. Canadian Journal 
of Public Health. 2006; 97(5): 409-411. 
26. McNeely J, Wu L-T, Subramaniam G, Sharma 
G, Cathers LA, Svikis D, et al. Performance of 
the tobacco, alcohol, prescription medication, 
85 
 
JOURNAL OF COMMUNITY MEDICINE AND PRIMARY HEALTH CARE VOL. 32, NO 1, MARCH 2020 
and other substance use (TAPS) tool for 
substance use screening in primary care 
patients. Annals of Internal Medicine. 2016; 
165(10): 690-699. 
27.  Patel V, Chisholm D, Parikh R, Charlson FJ, 
Degenhardt L, Dua T, et al. Addressing the 
burden of mental, neurological, and 
substance use disorders: key messages from 
Disease Control Priorities. The Lancet. 2016; 
387(10028): 1672-1685. 
28. Araoye MO. Sample size determination. 
Research methodology with statistics for 
health and social sciences Ilorin: Nathadex 
Publishers. 2004: 115-121. 
29. Igwe W, Ojinnaka N, Ejiofor S, Emechebe G, 
Ibe B. Socio-demographic correlates of 
psychoactive substance abuse among 
secondary school students in Enugu, Nigeria. 
European  Journal of  Social Sciences. 2009; 
12(2): 1-7. 
30.  WHO ASSIST Working Group. The alcohol, 
smoking and substance involvement 
screening test (ASSIST): development, 
reliability and feasibility. Addiction. 2002; 
97(9): 1183-1194. 
31.  Onifade P, Bello A, Abiodun O, Sotunsa J, 
Ladipo O. Psychometric Properties of Alcohol 
Smoking and Substance Involvement 
Screening Test (Assist V3. 0) Among 
University Students. Journal of  Addictive 
Behaviours, Therapy & Rehabilitation, 2014; 
3(3): doi: 10.4172/2324-9005. 1000126 
32.  Humeniuk R, Ali R, Babor TF, Farrell M, 
Formigoni ML, Jittiwutikarn J, et al. 
Validation of the alcohol, smoking and 
substance involvement screening test 
(ASSIST). Addiction. 2008; 103(6): 1039-
1047. 
33. Lasebikan VO, Ola BA. Prevalence and 
correlates of alcohol use among a sample of 
Nigerian semirural community dwellers in 
Nigeria. Journal of Addiction. 2016; 2016. 
34. Sowunmi OA, Amoo G, Onifade PO, Ogunwale 
A, Babalola E. Psychoactive substance use 
among outpatients with severe mental 
illness: A comparative study. South African 
Journal of Psychiatry. 2019; 25(1): 1-7. 
35. Fink-Miller EL, Long DM, Gross RT. 
Comparing chronic pain treatment seekers in 
primary care versus tertiary care settings. 
The Journal of  American  Board of Family 
Medicine. 2014; 27(5): 594-601. 
36.  Alford DP, German JS, Samet JH, Cheng DM, 
Lloyd-Travaglini CA, Saitz R. Primary care 
patients with drug use report chronic pain 
and self-medicate with alcohol and other 
drugs. Journal of General Internal Medicine. 
2016; 31(5): 486-491. 
37. Anthierens S, Pasteels I, Habraken H, 
Steinberg P, Declercq T, Christiaens T. 
Barriers to non-pharmacologic treatments for 
stress, anxiety, and insomnia: Family 
physicians’ attitudes toward benzodiazepine 
prescribing. Canadian Family Physician. 
2010; 56(11): e398-e406. 
38.  Adebayo S, Oladele O. Medicinal values of 
Kolanut in Nigeria: implication for extension 
service delivery. Life Science Journal. 2012; 
9(2): 887-891. 
39.  Okpataku CI, Kwanashie HO, Ejiofor JI, 
Olisah VO. Prevalence and socio-
demographic risk factors associated with 
psychoactive substance use in psychiatric 
out-patients of a tertiary hospital in Nigeria. 
Nigerian Medical Journal. 2014; 55(6): 460. 
40.  Hall W, Degenhardt L. Adverse health effects 
of non-medical cannabis use. The Lancet. 
2009; 374(9698): 1383-1391. 
41.  McNeely J, Strauss SM, Wright S, Rotrosen 
J, Khan R, Lee JD, et al. Test-retest reliability 
of a self-administered Alcohol, Smoking and 
Substance Involvement Screening Test 
(ASSIST) in primary care patients. Journal of 
Substance Abuse Treatment. 2014; 47(1): 93-
101. 
42.  Dawson-Rose C, Draughon JE, Zepf R, Cuca 
YP, Huang E, Freeborn K, et al. Prevalence of 
substance use in an HIV primary care safety 
net clinic: A call for screening. Journal of the 
Association of Nurses in AIDS Care. 2017; 
28(2): 238-249. 
43.  Bruijnzeel AW. Tobacco addiction and the 
dysregulation of brain stress systems. 
Neuroscience & Biobehavioral Reviews. 2012; 
36(5): 1418-1441. 
44. Kolodny A, Courtwright DT, Hwang CS, 
Kreiner P, Eadie JL, Clark TW, et al. The 
prescription opioid and heroin crisis: a public 
86 
 
JOURNAL OF COMMUNITY MEDICINE AND PRIMARY HEALTH CARE VOL. 32, NO 1, MARCH 2020 
health approach to an epidemic of addiction. 
Annual Review of Public Health. 2015; 36: 
559-574. 
45.  Ward CL, Mertens JR, Flisher AJ, Bresick GF, 
Sterling SA, Little F, et al. Prevalence and 
correlates of substance use among South 
African primary care clinic patients. 
Substance Use & Misuse. 2008; 43(10): 
1395-1410. 
46.  Erinfolami A, Olagunju A, Oguntuase A, 
Akinbode A. P03-208-Correlates and 
prevalence of substance use among primary 
care patient in Ikorodu, Nigeria. European 
Psychiatry. 2010; 25: 1274. 
47.  Babalola E, Akinhanmi A, Ogunwale A. Who 
guards the guards: drug use pattern among 
medical students in a Nigerian University. 
Annals of Medical and Health Sciences 
Research. 2014; 4(3): 397-403. 
48. Wu L-T, McNeely J, Subramaniam GA, Brady 
KT, Sharma G, VanVeldhuisen P, et al. DSM-
5 substance use disorders among adult 
primary care patients: Results from a 
multisite study. Drug and Alcohol 
Dependence. 2017; 179: 42-46. 
49. Becker JB, McClellan ML, Reed BG. Sex 
differences, gender and addiction. Journal of 
Neuroscience Research. 2017; 95(1-2):136-
47. 
50.  Becker JB, Perry AN, Westenbroek C. Sex 
differences in the neural mechanisms 
mediating addiction: a new synthesis and 
hypothesis. Biology of Sex Differences. 2012; 
3(1): 14. 
51. Akanni OO, Koleoso ON, Olashore AA, 
Adayonfo EO, Osundina AF, Ayilara OO. 
Gender and other risk factors associated with 
risky behaviours among Nigerian 
adolescents. Journal of Adolescence. 2017; 
57: 13-17. 
52.  Molton IR, Terrill AL. Overview of persistent 
pain in older adults. American Psychologist. 
2014; 69(2): 197. 
53. Grant JD, Scherrer JF, Lynskey MT, Agrawal 
A, Duncan AE, Haber JR, et al. Associations 
of alcohol, nicotine, cannabis, and drug 
use/dependence with educational 
attainment: Evidence from Cotwin‐Control 
analyses. Alcoholism: Clinical and 
Experimental Research. 2012; 36(8):1412-
1420. 
54. Koenig HG. Research on religion, spirituality, 
and mental health: A review. The Canadian 
Journal of Psychiatry. 2009; 54(5): 283-291. 
55.  Stringfellow EJ, Kim TW, Gordon AJ, Pollio 
DE, Grucza RA, Austin EL, et al. Substance 
use among persons with homeless experience 
in primary care. Substance abuse. 2016; 
37(4): 534-541. 
56. Erinfolami A, Eegunranti A, Ogunsemi O, 
Oguntuase A, Akinbode A, Erinfolami G. 
Prevalence and associated risk factors of Kola 
nut chewing among secondary school 
students in Osogbo, Nigeria. Mental Illness. 
2011; 3(1): e6. 
57. Newcombe DA, Humeniuk RE, Ali R. 
Validation of the world health organization 
alcohol, smoking and substance involvement 
screening test (ASSIST): report of results from 
the Australian site. Drug and Alcohol Review. 
2005; 24(3): 217-226. 
58. Henry-Edwards S, Humeniuk R, Ali R, 
Poznyak V, Monteiro M. The alcohol, smoking 
and substance involvement screening test 
(ASSIST): Guidelines for use in primary care 
(draft version 1.1 for field testing). Geneva: 
World Health Organization. 2003. 
 
 
 
 
 
 
 
